Bio-Rad Laboratories (BIO) is a Classic Ariel Stock: Ariel Fund — Oct 15th, 2024

Ariel Investments, an investment management company, released its “Ariel Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to the economy's resilience and forecasters' expectations of a soft landing, all major U.S. indices saw gains in the thir...

BIO Gears Up for Q3 Earnings: Here's What You Need to Know — Oct 17th, 2024

Bio-Rad Laboratories, Inc. BIO is scheduled to release third-quarter 2024 results on Oct. 30, after the closing bell. The company posted adjusted earnings per share (EPS) of $3.11 in the last reported quarter, which beat the Zacks Consensus Estimate by 46.7%. Bio-Rad beat on earnings in...

BIO Gears Up for Q3 Earnings: Here's What You Need to Know — Oct 17th, 2024

Bio-Rad Laboratories, Inc. BIO is scheduled to release third-quarter 2024 results on Oct. 30, after the closing bell. The company posted adjusted earnings per share (EPS) of $3.11 in the last reported quarter, which beat the Zacks Consensus Estimate by 46.7%. Bio-Rad beat on earnings in...

Bio-Rad Laboratories (BIO) is a Classic Ariel Stock: Ariel Fund — Oct 15th, 2024

Ariel Investments, an investment management company, released its “Ariel Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to the economy's resilience and forecasters' expectations of a soft landing, all major U.S. indices saw gains in the thir...

Should You Continue to Hold Bio-Rad Stock in Your Portfolio? — Oct 1st, 2024

Bio-Rad Laboratories, Inc.’s BIO robust QX600 Droplet Digital PCR (ddPCR) platform positions the company well to capture a major share in the booming digital PCR space. The clinical diagnostics business continues to gain momentum while building a position in new molecular diagnostics are...

BIO Gears Up for Q3 Earnings: Here's What You Need to Know — Oct 17th, 2024

Bio-Rad Laboratories, Inc. BIO is scheduled to release third-quarter 2024 results on Oct. 30, after the closing bell. The company posted adjusted earnings per share (EPS) of $3.11 in the last reported quarter, which beat the Zacks Consensus Estimate by 46.7%. Bio-Rad beat on earnings in...

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 — Oct 14th, 2024

HERCULES, Calif., October 14, 2024--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2024 on Wednesday, October 30, 2024, following the c...

BIO Gears Up for Q3 Earnings: Here's What You Need to Know — Oct 17th, 2024

Bio-Rad Laboratories, Inc. BIO is scheduled to release third-quarter 2024 results on Oct. 30, after the closing bell. The company posted adjusted earnings per share (EPS) of $3.11 in the last reported quarter, which beat the Zacks Consensus Estimate by 46.7%. Bio-Rad beat on earnings in...

BIO Gears Up for Q3 Earnings: Here's What You Need to Know — Oct 17th, 2024

Bio-Rad Laboratories, Inc. BIO is scheduled to release third-quarter 2024 results on Oct. 30, after the closing bell. The company posted adjusted earnings per share (EPS) of $3.11 in the last reported quarter, which beat the Zacks Consensus Estimate by 46.7%. Bio-Rad beat on earnings in...

Should You Continue to Hold Bio-Rad Stock in Your Portfolio? — Oct 1st, 2024

Bio-Rad Laboratories, Inc.’s BIO robust QX600 Droplet Digital PCR (ddPCR) platform positions the company well to capture a major share in the booming digital PCR space. The clinical diagnostics business continues to gain momentum while building a position in new molecular diagnostics are...

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 — Oct 14th, 2024

HERCULES, Calif., October 14, 2024--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2024 on Wednesday, October 30, 2024, following the c...

BIO Gears Up for Q3 Earnings: Here's What You Need to Know — Oct 17th, 2024

Bio-Rad Laboratories, Inc. BIO is scheduled to release third-quarter 2024 results on Oct. 30, after the closing bell. The company posted adjusted earnings per share (EPS) of $3.11 in the last reported quarter, which beat the Zacks Consensus Estimate by 46.7%. Bio-Rad beat on earnings in...

Bio-Rad Laboratories (BIO) is a Classic Ariel Stock: Ariel Fund — Oct 15th, 2024

Ariel Investments, an investment management company, released its “Ariel Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to the economy's resilience and forecasters' expectations of a soft landing, all major U.S. indices saw gains in the thir...

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 — Oct 14th, 2024

HERCULES, Calif., October 14, 2024--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2024 on Wednesday, October 30, 2024, following the c...

BIO Gears Up for Q3 Earnings: Here's What You Need to Know — Oct 17th, 2024

Bio-Rad Laboratories, Inc. BIO is scheduled to release third-quarter 2024 results on Oct. 30, after the closing bell. The company posted adjusted earnings per share (EPS) of $3.11 in the last reported quarter, which beat the Zacks Consensus Estimate by 46.7%. Bio-Rad beat on earnings in...

Bio-Rad Laboratories (BIO) is a Classic Ariel Stock: Ariel Fund — Oct 15th, 2024

Ariel Investments, an investment management company, released its “Ariel Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to the economy's resilience and forecasters' expectations of a soft landing, all major U.S. indices saw gains in the thir...

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 — Oct 14th, 2024

HERCULES, Calif., October 14, 2024--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2024 on Wednesday, October 30, 2024, following the c...

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 — Oct 14th, 2024

HERCULES, Calif., October 14, 2024--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2024 on Wednesday, October 30, 2024, following the c...

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 — Oct 14th, 2024

HERCULES, Calif., October 14, 2024--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2024 on Wednesday, October 30, 2024, following the c...

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 — Oct 14th, 2024

HERCULES, Calif., October 14, 2024--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2024 on Wednesday, October 30, 2024, following the c...

BIO Gears Up for Q3 Earnings: Here's What You Need to Know — Oct 17th, 2024

Bio-Rad Laboratories, Inc. BIO is scheduled to release third-quarter 2024 results on Oct. 30, after the closing bell. The company posted adjusted earnings per share (EPS) of $3.11 in the last reported quarter, which beat the Zacks Consensus Estimate by 46.7%. Bio-Rad beat on earnings in...

Bio-Rad Laboratories (BIO) is a Classic Ariel Stock: Ariel Fund — Oct 15th, 2024

Ariel Investments, an investment management company, released its “Ariel Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to the economy's resilience and forecasters' expectations of a soft landing, all major U.S. indices saw gains in the thir...

Should You Continue to Hold Bio-Rad Stock in Your Portfolio? — Oct 1st, 2024

Bio-Rad Laboratories, Inc.’s BIO robust QX600 Droplet Digital PCR (ddPCR) platform positions the company well to capture a major share in the booming digital PCR space. The clinical diagnostics business continues to gain momentum while building a position in new molecular diagnostics are...

BIO Gears Up for Q3 Earnings: Here's What You Need to Know — Oct 17th, 2024

Bio-Rad Laboratories, Inc. BIO is scheduled to release third-quarter 2024 results on Oct. 30, after the closing bell. The company posted adjusted earnings per share (EPS) of $3.11 in the last reported quarter, which beat the Zacks Consensus Estimate by 46.7%. Bio-Rad beat on earnings in...

Should You Continue to Hold Bio-Rad Stock in Your Portfolio? — Oct 1st, 2024

Bio-Rad Laboratories, Inc.’s BIO robust QX600 Droplet Digital PCR (ddPCR) platform positions the company well to capture a major share in the booming digital PCR space. The clinical diagnostics business continues to gain momentum while building a position in new molecular diagnostics are...

Bio-Rad Laboratories (BIO) is a Classic Ariel Stock: Ariel Fund — Oct 15th, 2024

Ariel Investments, an investment management company, released its “Ariel Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to the economy's resilience and forecasters' expectations of a soft landing, all major U.S. indices saw gains in the thir...

Bio-Rad Laboratories (BIO) is a Classic Ariel Stock: Ariel Fund — Oct 15th, 2024

Ariel Investments, an investment management company, released its “Ariel Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to the economy's resilience and forecasters' expectations of a soft landing, all major U.S. indices saw gains in the thir...

Should You Continue to Hold Bio-Rad Stock in Your Portfolio? — Oct 1st, 2024

Bio-Rad Laboratories, Inc.’s BIO robust QX600 Droplet Digital PCR (ddPCR) platform positions the company well to capture a major share in the booming digital PCR space. The clinical diagnostics business continues to gain momentum while building a position in new molecular diagnostics are...

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 — Oct 14th, 2024

HERCULES, Calif., October 14, 2024--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2024 on Wednesday, October 30, 2024, following the c...

Bio-Rad Laboratories (BIO) is a Classic Ariel Stock: Ariel Fund — Oct 15th, 2024

Ariel Investments, an investment management company, released its “Ariel Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to the economy's resilience and forecasters' expectations of a soft landing, all major U.S. indices saw gains in the thir...

Should You Continue to Hold Bio-Rad Stock in Your Portfolio? — Oct 1st, 2024

Bio-Rad Laboratories, Inc.’s BIO robust QX600 Droplet Digital PCR (ddPCR) platform positions the company well to capture a major share in the booming digital PCR space. The clinical diagnostics business continues to gain momentum while building a position in new molecular diagnostics are...

Should You Continue to Hold Bio-Rad Stock in Your Portfolio? — Oct 1st, 2024

Bio-Rad Laboratories, Inc.’s BIO robust QX600 Droplet Digital PCR (ddPCR) platform positions the company well to capture a major share in the booming digital PCR space. The clinical diagnostics business continues to gain momentum while building a position in new molecular diagnostics are...

Should You Continue to Hold Bio-Rad Stock in Your Portfolio? — Oct 1st, 2024

Bio-Rad Laboratories, Inc.’s BIO robust QX600 Droplet Digital PCR (ddPCR) platform positions the company well to capture a major share in the booming digital PCR space. The clinical diagnostics business continues to gain momentum while building a position in new molecular diagnostics are...